|
1
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Johnston SRD and Dowsett M: Aromatase
inhibitors for breast cancer: Lessons from the laboratory. Nat Rev
Cancer. 3:821–831. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Baselga J and Swain SM: Novel anti-cancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
|
|
5
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cell. 10:515–527.
2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Subik K, Lee JF, Baxter L, Strezepel T,
Costello D, Crowley P, Xing L, Hung MC and Bonfiglio T: Expression
patterns of ER, PR, HER-2, CK5/6, Ki-67and AR by
immune-histochemical analysis in breast cancer cell lines. Breast
Cancer. 4:35–41. 2010.PubMed/NCBI
|
|
7
|
Gupta A, Mehta R, Alimirah F, Peng X,
Murillo G, Weihle R and Mehta RG: Efficacy and mechanism of action
Proellex, an anti-progestin in aromatase over-expressing and
letrozole resistant T47D breast cancer cells. J Steroid Biochem Mol
Biol. 133:30–42. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hole S, Pedersen AM, Hansen SK, Lundqvist
J, Yde CW and Lykkesfeldt AE: A new cell culture model for
aromatase resistant breast cancer shows sensitivity to fluvestrant
treatment and cross resistance between letrozole and exemestane.
Int J Oncol. 46:1481–1490. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Dey P, Rathod M and De A: Targeting stem
cells in the realm of drug-resistant breast cancer. Breast Cancer
(Dove Med Press). 11:115–135. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Stampfer MR and Bartley JC: Induction of
transformation and continuous cell lines from normal human mammary
epithelial cell lines after exposure to benzo[a]pyrene. Proc Natl.
Acad Sci USA. 82:2394–2398. 1985.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhai WF, Beittenmiller H, Wang B, Gould
MN, Oakley C, Esselman WJ and Welch CW: Increased expression of
protein tyrosine phosphatases in human breast epithelial cells
neoplastically transformed by the neu oncogene. Cancer Res.
53:2272–2278. 1993.PubMed/NCBI
|
|
12
|
Telang N: Targeting drug resistant stem
cells in a human epidermal growth factor receptor-2-enriched breast
cancer model. World Acad Sci J. 1:86–91. 2019.
|
|
13
|
Katdare M, Osborne M and Telang NT: Soy
isoflavone genestein modulates cell cycle progression and induces
apoptosis in HER-2 oncogene expressing human breast epithelial
cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI
|
|
14
|
Telang NT, Katdare M, Bradlow HL, Osborne
MP and Fishman J: Inhibition of proliferation and modulation of
estradiol metabolism: Novel mechanisms for breast cancer prevention
by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med.
216:246–252. 1997.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Katdare M, Jinno H, Osborne MP and Telang
NT: Negative growth regulation of oncogene-transformed human breast
epithelial cells by phytochemicals: Role of apoptosis. Ann NY Acad
Sci. 889:247–252. 1999.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Telang N: Anti-proliferative and
pro-apoptotic effects of rosemary and constituent terpenoids in a
model for HER-2-enriched molecular subtype of clinical breast
cancer. Oncol Letts. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Subbaramaiah K, Cole PA and Dannenberg AJ:
Retinoids and carnosol suppress cyclooxygenase-2 transcription by
CREB-binding protein/p300 dependent- and-independent mechanisms.
Cancer Res. 62:2522–2530. 2002.PubMed/NCBI
|
|
18
|
Rahman KM, Li Y and Sarkar FH:
Inactivation of Akt and NF-kappaB play important roles during
indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr
Cancer. 48:84–94. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schroder L, Marahrens P, Koch GJ,
Heidegger H, Vilsmeier T, Phan-Brehm T, Hofmann S, Mahner S,
Jeschke U and Richter DU: Effects of green tea, matcha tea and
their components epigallocatechin gallate and quercetin on MCF-7
and MDA-MB-231 breast carcinoma cells. Oncol Rep. 41:387–396.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kabala-Dzik A, Rzepecka-Stojko A, Kubina
R, Iriti M, Wojtyczka RD, Buszman E and Stojko J: Flavonoids,
bioactive components of Propolis, exhibit cytotoxic activity and
induce cell cycle arrest and apoptosis in human breast cancer cells
MDA-MB-231 and MCF-7-a comparative study. Cell Mol Biol
(Noisy-le-Grand). 64:1–10. 2018.PubMed/NCBI
|
|
21
|
Al-Daheri Y, Attoub S, Ramadan G, Arafat
K, Bajbouj K, Karuvantevida N, AbuQamar S, Eid A and Iratni R:
Carnosol induces ROS-mediated beclin1-independent autophagy and
apoptosis in triple negative breast cancer. PLoS One.
9(e109630)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rusnak DW, Lackey K, Affleck K, Wood ER,
Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ
and Gilmer TM: The effects of the novel, reversible epidermal
growth factor/ErB2 tyrosine kinase inhibitor, GW2016, on the growth
of human normal and tumor-derived cell lines. Mol Cancer Ther.
1:85–94. 2001.PubMed/NCBI
|
|
23
|
Nahta R, Yuan LXH, Du Y and Esteva FJ:
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer
cells: Effect on insulin-like growth factor I signaling. Mol Cancer
Ther. 6:667–674. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nguyen PH, Giraud J, Staedel C,
Chambonnier L, Dubus P, Chevret E, Boeuf H, Gauthereau X, Rousseau
B, Fevre M, et al: All-trans retinoic acid targets gastric cancer
stem cells and inhibits patient-derived gastric carcinoma tumor
growth. Oncogene. 35:5619–5628. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kallifatidis G, Labsch S, Rausch V,
Mattern J, Galdkich J, Moldenhauer D, Buchler MW, Salinikov AV and
Herr I: Sulphoraphane increases drug-mediated cytotoxicity toward
cancer stem-like cells of pancreas and prostate. Mol Cancer Ther.
19:188–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Castro NP, Rangel MC, Merchant AS,
MacKinnon G, Cuttitta F, Salomon DA and Kim YS: Sulphoraphane
suppresses the growth of triple negative breast cancer stem-like
cells in vitro and in vivo. Cancer Prev Res (Phila). 12:147–158.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kim SH and Singh SV: Role of Kruppel-like
factor-4/p21CIP1 axis in breast cancer stem-like cell
inhibition by benzyl isothiocyanate. Cancer Prev Res (Phila).
12:125–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ye I, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of breast cancer and cancer metastasis.
Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Telang NT, Li G, Katdare M, Sepkovic DW,
Bradlow HL and Wong GY: The nutritional herb Epimedium
grandiflorum inhibits the growth in a model for the Luminal A
molecular subtype of breast cancer. Oncol Letts. 13:2477–2482.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Telang N, Nair HB and Wong GYC: Growth
inhibitory efficacy and anti-aromatase activity of Tabebuia
avellanedae in a model for post-menopausal Luminal A breast
cancer. Biomed Rep. 11:222–229. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Telang NT, Nair HB and Wong GYC: Growth
inhibitory efficacy of Cornus officinalis in a cell culture
model for triple negative breast cancer. Oncol Lett. 17:5261–5266.
2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang F, Zhang J and Yang H: OCT4, SOX2 and
NANOG positive expression correlates with poor differentiation,
advanced disease stages and worse overall survival in
HER-2+ breast cancer patients. Onco Targets Ther.
11:7873–7881. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bruna A, Rouda OM Greenwood A, Batra AS,
Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW,
Tufegdzic-Vidakocic A, et al: A biobank of breast cancer explants
with preserved intra-tumor heterogeneity to screen anti-cancer
compounds. Cell. 167:260–274.e22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber E, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018.PubMed/NCBI View Article : Google Scholar
|
